Orthocell posts record U.S. monthly sales of Remplir nerve wrap
Orthocell Limited has reported its strongest month of U.S. sales since launching Remplir, its collagen nerve wrap for peripheral nerve repair and protection, with 92 units sold in October 2026 generating AU$279,000 in revenue. The result represents an 84% uplift on the average of 50 units sold per month during the first quarter of the company's 2027 financial year.
The Perth-based company made the announcement ahead of its Annual General Meeting on 6 November 2026, departing from its standard quarterly reporting cadence to give shareholders an early commercial update. Orthocell is listed on the Australian Securities Exchange under the ticker OCC.
Commercial drivers
Chief executive and managing director Paul Anderson said October's result reflects 12 months of groundwork in the U.S. market now converting into revenue. "The improvement in key commercial indicators demonstrates that Remplir is gaining traction in the U.S. market," he said. "Our focus remains on accelerating surgeon adoption, expanding hospital access and increasing product utilisation."
The company attributed the uplift to four factors: growing surgeon familiarity with the device, increasing repeat use among existing customers, an expanded network of actively selling distributor representatives, and broader hospital access secured through Value Assessment Committee approvals. Hospital VAC processes are a well-known friction point in U.S. medtech commercialisation, as new devices must clear institutional procurement reviews before clinical staff can use them routinely. Progress on this front is typically slow in the early years after launch, making October's jump in unit sales a meaningful indicator.
Chairman John Van Der Wielen noted that the company has been expanding manufacturing capacity in Western Australia in anticipation of increased demand, and said the board remains confident in Remplir's long-term U.S. market potential.
Market context and competitive landscape
The peripheral nerve repair market is a relatively specialised segment within surgical medtech, covering products used in procedures ranging from trauma surgery to elective hand and wrist operations. It sits alongside established categories such as synthetic nerve conduits and autograft techniques, with a number of companies competing on biocompatibility, ease of handling, and clinical evidence. Collagen-based wraps like Remplir occupy a niche that emphasises protection and guidance rather than bridging large nerve gaps, and surgeon education is typically the primary commercial lever in the early adoption phase.
Orthocell says Remplir holds regulatory approvals across seven international jurisdictions beyond the United States, which provides a broader revenue base as U.S. commercialisation scales. The company will need to sustain the October growth rate over several quarters to demonstrate durable momentum rather than a one-month spike; investors will look for Q2 FY27 figures as the next meaningful data point.
No guidance on full-year revenue targets was included in the release, and the company has not disclosed the total number of U.S. surgeon accounts currently active on the product.